Effectiveness of Self-posturotherapy on the Elimination of Residual Fragments After Treatment of Lower Calyx Urinary Stones by Extracorporeal Lithotripsy or Retrograde Flexible Ureteroscopy. (ALUR)

The main objective of this study is to evaluate the effectiveness of an auto posturotherapy technique on the RFS at three months of patients treated for lower calyceal urinary stones by extracorporeal lithotripsy (ECL) or retrograde flexible ureteroscopy.

Study Overview

• Status: Recruiting
• Conditions: Stone, Kidney
• Intervention / Treatment: Behavioral: SELF POSTUROTHERAPIE

• Study Type: Interventional
• Enrollment (Estimated): 216
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Lyon, France, 69003
    • Recruiting
    • Hôpital Edouard Herriot -
    • Contact: Nadia ABID -, Dr; Phone Number: 04 72 11 80 88; Email: nadia.abid@chu-lyon.fr
  • Quint-Fonsegrives, France, 31130
    • Recruiting
    • Clinique La Croix Du Sud
    • Contact: Christophe ALMERAS, Dr; Phone Number: +33 05 36 28 00 00; Email: c.almeras@gmail.com
    • Principal Investigator: Christophe ALMERAS, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

pré Inclusion Criteria:

• Patient having read and signed the consent form for participation in the study • Patient candidate for an intervention on a lower calyx stone <15mm by LEC or URSS

Patients meeting all of the following criteria may be definitively included in the study:

• Patient treated by LEC, or patient treated by URSS and for whom the presence of lower calyceal fragments has been observed by endoscopy
• Absence of JJ stent (patients for whom a JJ stent was implanted after URSS or before LEC may be included as soon as it is removed)

Exclusion Criteria:

• Patients presenting one of the following criteria will not be included in the study:

  • Renal or ureteral malformation: ureteral stenosis, pyelo-ureteral junction syndrome, horseshoe kidney, para calyceal diverticulum, pelvic kidney.
  • LEC session interrupted due to treatment intolerance
  • Physical disability making posturotherapy impossible (particularly spinal, etc.), morbid obesity, major gastroesophageal reflux, heart or respiratory failure.
  • Balance disorder which would not allow self-posturotherapy to be carried out alone.
  • Patient under legal protection, under guardianship or under curatorship
  • Posturotherapy carried out while wearing a JJ probe
  • Posturotherapy carried out by a third party (physiotherapist or other)
  • Pregnant or breastfeeding patient
  • Patient not affiliated to the French social security system
  • Impossibility of providing the subject with informed information and/or giving written informed consent: dementia, psychosis, disorders of consciousness, non-French speaking patient
  • Treatment that may modify the clearance of fragments (beta blocker, diuretic, etc.)
  • Patient included in another therapeutic study protocol

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: self-posturotherapy; standard care (according to recommendations) + self-posturotherapy program	Behavioral: SELF POSTUROTHERAPIE; a simplified posturotherapy protocol that can be carried out by the patient himself. This protocol is based on the same principles as posturotherapy carried out by a physiotherapist by combining inclined positioning, percussion and diuresis.
No Intervention: Standard care; standard care alone (according to recommendations)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
stone free rate	3 month

Collaborators and Investigators

• Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche

Study record dates

Study Major Dates

• Study Start (Actual): June 30, 2025
• Primary Completion (Estimated): May 1, 2027
• Study Completion (Estimated): May 1, 2027

Study Registration Dates

• First Submitted: January 20, 2025
• First Submitted That Met QC Criteria: January 20, 2025
• First Posted (Actual): January 27, 2025

Study Record Updates

• Last Update Posted (Estimated): July 8, 2025
• Last Update Submitted That Met QC Criteria: July 2, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Male Urogenital Diseases; Calculi; Pathological Conditions, Anatomical; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Kidney Calculi; Nephrolithiasis; Urinary Calculi; Urolithiasis
• Other Study ID Numbers: 2023-06-024-ALMERAS(ALUR); 2024-A02267-40 (Other Identifier: Numéro ID RCB ( ANSM))

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No